Synthesis and biological evaluation of new 3(2H)-pyridazinone derivatives as non-toxic anti-proliferative compounds against human colon carcinoma HCT116 cells
Özet
Novel 3(2H)-pyridazinone derivatives were designed, synthesised in satisfactory yields and evaluated in different experimental assays to assess their preliminary toxicity in vivo and anti-proliferative effects against HCT116 cell lines in vitro. Artemia salina lethality test provided LC50 values >100 µg/mL for all compounds. Successive assays revealed that some compounds were endowed with a promising anti-proliferative effect against HCT116 cells, alone or stimulated by serotonin as a pro-inflammatory factor in order to mimick an inflamed model in vivo of cancer cell microenvironment. Moreover, the kinurenic acid level after treatment with these newly synthesised compounds was monitored as a marker of anti-proliferation in colon carcinoma models. The IC50 values obtained for the best-in-class compounds were comparable to that of daunorubicin as a reference drug. Conversely, these compounds were not able to counteract the spontaneous migration of human cancer HCT116 cell line in the wound healing paradigm. © 2020, © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Özdemir, Zeynep | |
| dc.contributor.author | Utku, Semra | |
| dc.contributor.author | Mathew, Bijo | |
| dc.contributor.author | Carradori, Simone | |
| dc.contributor.author | Orlando, Giustino | |
| dc.contributor.author | Di Simone, Simonetta | |
| dc.contributor.author | Alagöz, Mehmet Abdullah | |
| dc.contributor.author | Özçelik, Azime Berna | |
| dc.contributor.author | Uysal, Mehtap | |
| dc.contributor.author | Ferrante, Claudio | |
| dc.date.accessioned | 2026-10-18T20:28:29.011896710Z | |
| dc.date.available | 2026-10-18T20:28:29.011896710Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Novel 3(2H)-pyridazinone derivatives were designed, synthesised in satisfactory yields and evaluated in different experimental assays to assess their preliminary toxicity in vivo and anti-proliferative effects against HCT116 cell lines in vitro. Artemia salina lethality test provided LC50 values >100 µg/mL for all compounds. Successive assays revealed that some compounds were endowed with a promising anti-proliferative effect against HCT116 cells, alone or stimulated by serotonin as a pro-inflammatory factor in order to mimick an inflamed model in vivo of cancer cell microenvironment. Moreover, the kinurenic acid level after treatment with these newly synthesised compounds was monitored as a marker of anti-proliferation in colon carcinoma models. The IC50 values obtained for the best-in-class compounds were comparable to that of daunorubicin as a reference drug. Conversely, these compounds were not able to counteract the spontaneous migration of human cancer HCT116 cell line in the wound healing paradigm. © 2020, © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. | |
| dc.description.sponsorship | This work was supported by intramural grants by Ministero Italiano dell’Università e della Ricerca (MIUR) FAR 2019 (ex 60%), held by Dr. Simone Carradori. | |
| dc.identifier.doi | 10.1080/14756366.2020.1755670 | |
| dc.identifier.eissn | 1475-6374 | |
| dc.identifier.endpage | 1109 | |
| dc.identifier.issn | 1475-6366 | |
| dc.identifier.issue | 1 | |
| dc.identifier.pmcid | PMC7191905 | |
| dc.identifier.pmid | 32321320 | |
| dc.identifier.scopus | 2-s2.0-85083782939 | |
| dc.identifier.startpage | 1100 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/13649 | |
| dc.identifier.volume | 35 | |
| dc.identifier.wos | WOS:000527814500001 | |
| dc.language.iso | en | |
| dc.publisher | Taylor and Francis Ltd | |
| dc.relation.ispartof | Journal of Enzyme Inhibition and Medicinal Chemistry | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | anti-proliferative agents | |
| dc.subject | Artemia salina lethality test | |
| dc.subject | HCT116 | |
| dc.subject | kynurenic acid | |
| dc.subject | pyridazinone | |
| dc.subject | Serotonin | |
| dc.subject | wound healing | |
| dc.subject | Antineoplastic Agents | |
| dc.subject | Cell Proliferation | |
| dc.subject | Cell Survival | |
| dc.subject | Dose-Response Relationship, Drug | |
| dc.subject | Drug Screening Assays, Antitumor | |
| dc.subject | HCT116 Cells | |
| dc.subject | Humans | |
| dc.subject | Molecular Structure | |
| dc.subject | Pyridazines | |
| dc.subject | Structure-Activity Relationship | |
| dc.subject | Tumor Cells, Cultured | |
| dc.subject | antimitotic agent | |
| dc.subject | daunorubicin | |
| dc.subject | n' (2 bromobenzylidene) 2 [3 (3 fluoro 4 methoxyphenyl) 6 oxopyridazin 1(6h) yl]acetohydrazide | |
| dc.subject | n' (2 fluorobenzylidene) 2 [3 (3 fluoro 4 methoxyphenyl) 6 oxopyridazin 1(6h) yl]acetohydrazide | |
| dc.subject | n' (2 methoxybenzylidene) 2 [3 (3 fluoro 4 methoxyphenyl) 6 oxopyridazin 1(6h) yl]acetohydrazide | |
| dc.subject | n' (2 methylbenzylidene) 2 [3 (3 fluoro 4 methoxyphenyl) 6 oxopyridazin 1(6h) yl]acetohydrazide | |
| dc.subject | n' (2,4 dichlorobenzylidene) 2 [3 (3 fluoro 4 methoxyphenyl) 6 oxopyridazin 1(6h) yl]acetohydrazide | |
| dc.subject | n' (4 bromobenzylidene) 2 [3 (3 fluoro 4 methoxyphenyl) 6 oxopyridazin 1(6h) yl]acetohydrazide | |
| dc.subject | n' (4 fluorobenzylidene) 2 [3 (3 fluoro 4 methoxyphenyl) 6 oxopyridazin 1(6h) yl]acetohydrazide | |
| dc.subject | n' (4 hydroxybenzylidene) 2 [3 (3 fluoro 4 methoxyphenyl) 6 oxopyridazin 1(6h) yl]acetohydrazide | |
| dc.subject | n' (4 isopropylbenzylidene) 2 [3 (3 fluoro 4 methoxyphenyl) 6 oxopyridazin 1(6h) yl]acetohydrazide | |
| dc.subject | n' (4 methoxybenzylidene) 2 [3 (3 fluoro 4 methoxyphenyl) 6 oxopyridazin 1(6h) yl]acetohydrazide | |
| dc.title | Synthesis and biological evaluation of new 3(2H)-pyridazinone derivatives as non-toxic anti-proliferative compounds against human colon carcinoma HCT116 cells | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 23 | |
| rdl.citation.wos | 21 | |
| rdl.department | Department of Pharmaceutical Chemistry, Erzincan Binali Yıldırım University, Erzincan, Turkey. | |
| rdl.oa.status | gold | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) | |
| rdl.wos.index | Index Chemicus (IC) |
